Compare TNF Inhibitors

1 Product

reset all

At-a-Glance

Description

FDA

CE Mark

Active Ingredients

Application

Status

Strength

remove

Humira

AbbVie Inc.

Mechanism of Action: Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
Dosage: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of non-infectious intermediate, posterior and panuveitis (UV) in adults, among other uses.

Yes

Not specified

Adalimumab

Subcutaneous injection

Prescription

Formulation dependent

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.